Dr. Gerhardt Attard is a John Black Charitable Foundation Endowed Chair in Urological Cancer Research at University College London. He holds an advanced Cancer Research UK Clinician Scientist award and is the Team Leader of the Treatment Resistance Group at the UCL Cancer Institute. He graduated with a degree in Medicine from the University of Malta in June 1999 and obtained a PhD in Medicine from the University of London (ICR) in 2010. His main research interest is dissecting treatment resistance, currently with a focus on plasma DNA analysis, to inform the development of novel therapeutics and biomarkers for castration-resistant prostate cancer (CRPC).
Dr. Attard’s many awards over the years include the ASCO Foundation Annual Merit Award in 2007, the Prostate Cancer Foundation Young Investigator Award in 2008, the AACR-GlaxoSmithKline Outstanding Clinical Scholar Award in 2009, the Medical Research Society/Academy of Medical Sciences Sue McCarthy Prize in 2010, and the McElwain award in 2010. He received the Cancer Research UK Future Leader Award in 2017. Dr. Attard sits on several advisory boards and the editorial board of the Annals of Oncology.
Dr. Enrique Grande, MD, PhD, MSc, is the Director of the Medical Oncology Program and Clinical Research Lead at the MD Anderson Cancer Center Madrid. Dr. Grande focuses his research on genitourinary and endocrine tumors and actively collaborates in the development of the Translational Research and Early Drug Development Unit. Dr. Grande was awarded his PhD for a pharmacokinetic and pharmacodynamic study of tyrosine kinase inhibitors in liver metabolism, and he holds a master’s degree in the molecular biology of cancer from the Spanish National Cancer Research Centre (CNIO).
As a published author of more than 200 manuscripts in peer-reviewed journals, Dr. Grande is also the founder of the Spanish Group of Research on Orphan and Uncommon Tumours (GETHI). He serves as an editor for several international journals and has participated in the most recent trials in the field of bladder cancer that led to the approval of new drugs. Additionally, he chairs the steering committee of the IMVIGOR 130 trial.
